AbbVie shares fell 1.30% to $244.78, marking a seventh consecutive session of losses and underperforming the S&P 500. The decline follows revised earnings guidance below consensus estimates due to acquisition expenses. However, AbbVie received EU approval for an expanded Tepkinly label and maintains a Buy rating from analysts citing its Apogee Therapeutics acquisition. Despite mixed sentiment, Wall Street and Seeking Alpha analysts retain Buy recommendations.